{"result": "{\n    \"title\": \"Advancements and Challenges in Septic Shock Treatment\",\n    \"summary\": \"This report delves into the complex landscape of septic shock treatment, highlighting the pivotal roles of Drotrecogin Alfa (activated), Hydrocortisone plus Fludrocortisone therapy, and the APROCCHSS trial. It explores the evolution of treatment protocols, the impact of clinical trials on medical practices, and the regulatory decisions affecting drug availability. The relationships between entities such as Eli Lilly, intensive care units, and regulatory bodies underscore the collaborative efforts in addressing septic shock, a leading cause of death in ICUs worldwide.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the critical nature of septic shock treatment and the significant influence of clinical trials and regulatory decisions on patient outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"The pivotal role of Drotrecogin Alfa (activated) in septic shock treatment\",\n            \"explanation\": \"Drotrecogin Alfa (activated), also known as Xigris, was a groundbreaking treatment for septic shock, highlighting the pharmaceutical industry's efforts to combat this condition. Despite its initial approval and use, the drug was withdrawn from the market due to subsequent trials failing to confirm a survival benefit, marking a significant turn in the treatment landscape of septic shock. This withdrawal underscores the complexities and challenges in developing effective sepsis treatments and the importance of rigorous clinical evaluation. [Data: Entities (168, 372); Relationships (76, 5, 414, 413)]\"\n        },\n        {\n            \"summary\": \"Hydrocortisone plus Fludrocortisone therapy's effectiveness in septic shock\",\n            \"explanation\": \"The APROCCHSS trial demonstrated a survival benefit with Hydrocortisone plus Fludrocortisone therapy in adults with septic shock, offering a glimmer of hope in the fight against this deadly condition. This therapy's evaluation through rigorous clinical trials such as APROCCHSS and GERMED's support illustrates the ongoing search for effective septic shock treatments and the critical role of evidence-based medicine in guiding treatment protocols. [Data: Entities (382, 369, 375); Relationships (79, 75, 571, 563)]\"\n        },\n        {\n            \"summary\": \"The impact of the APROCCHSS trial on septic shock treatment protocols\",\n            \"explanation\": \"The APROCCHSS trial, supported by entities like the French Ministry of Social Affairs and Health, has been instrumental in advancing our understanding of septic shock treatment. By demonstrating the efficacy of Hydrocortisone plus Fludrocortisone, this trial has contributed to shaping current treatment guidelines, highlighting the importance of clinical research in improving patient outcomes. The involvement of intensive care units and the publication of trial results on platforms like NEJM.org further emphasize the collaborative effort in disseminating crucial medical knowledge. [Data: Entities (375, 285, 371); Relationships (192, 526, 564, 565)]\"\n        },\n        {\n            \"summary\": \"Regulatory bodies' role in the approval and review of septic shock treatments\",\n            \"explanation\": \"The European Medicines Agency and the Food and Drug Administration played crucial roles in the approval and subsequent review of Drotrecogin Alfa (activated), reflecting the regulatory challenges in ensuring the safety and efficacy of septic shock treatments. These agencies' decisions have a profound impact on the availability of treatments and underscore the importance of balancing innovation with patient safety. [Data: Entities (3, 4); Relationships (2, 3)]\"\n        },\n        {\n            \"summary\": \"The influence of Eli Lilly in the development and study of septic shock treatments\",\n            \"explanation\": \"Eli Lilly's involvement in producing Drotrecogin Alfa (activated) and sponsoring the PROWESS-SHOCK trial illustrates the pharmaceutical industry's role in researching and developing septic shock treatments. Despite the challenges faced with Drotrecogin Alfa (activated), Eli Lilly's commitment to advancing medical treatment through clinical trials remains evident, highlighting the complex interplay between pharmaceutical companies, clinical research, and treatment innovation. [Data: Entities (1, 7); Relationships (10, 1, 6)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n168,DROTRECOGIN ALFA (ACTIVATED),\"Drotrecogin alfa (activated) was a medication with antithrombotic, antiinflammatory, and profibrinolytic properties, initially used in the treatment of severe sepsis and septic shock. It is a recombinant human activated protein C. Despite its early use, Drotrecogin alfa (activated) was withdrawn from the market in 2011 due to subsequent trials that did not confirm its survival benefit for patients. This decision followed its examination in various studies, including the APROCCHSS trial, which tested its effectiveness in patients with septic shock, particularly in combination with corticosteroids. However, its relevance and use in clinical practice diminished following its market withdrawal, marking the end of its consideration as a therapeutic option for septic shock.\",7\n382,HYDROCORTISONE PLUS FLUDROCORTISONE,A treatment regimen used in clinical trials to assess its effectiveness in reducing mortality and the need for vasopressors in patients with septic shock,6\n34,INTENSIVE CARE UNITS (ICUS),\"Intensive Care Units (ICUs) are critical medical facilities that play a pivotal role in the healthcare system, especially for patients with severe and life-threatening conditions. They are the primary setting for the treatment of septic shock, which stands as the most common cause of death in these units. Furthermore, ICUs were the designated locations for patients eligible for the APROCCHSS trial, highlighting their importance in conducting critical medical research and trials aimed at improving patient outcomes. These units are equipped with advanced medical technologies and staffed by specialized healthcare professionals dedicated to providing high-level care to critically ill patients.\",3\n31,GROUPE D'ETUDE ET DE RECHERCHE SUR LE MÉDICAMENT (GERMED),The organization that supported the septic shock study with a grant from publicly funded resources,2\n369,HYDROCORTISONE-PLUS-FLUDROCORTISONE,\"A therapy evaluated in a clinical trial for its effectiveness in treating septic shock, showing a reduction in 90-day all-cause mortality compared to placebo\",2\n2,PROWESS-SHOCK,A clinical trial comparing DrotAA with placebo in patients with septic shock to assess mortality rates,2\n375,APROCCHSS TRIAL,\"The APROCCHSS TRIAL, also known as the Activated Protein C and Corticosteroids for Human Septic Shock trial, was designed to evaluate the benefits and risks of corticosteroids and drotrecogin alfa (activated) in patients with septic shock. This clinical trial demonstrated a survival benefit with the use of hydrocortisone plus fludrocortisone in adults who were experiencing septic shock with persistent vasopressor dependency and organ failures. Through its comprehensive approach, the APROCCHSS TRIAL has contributed valuable insights into the management and treatment of septic shock, highlighting the potential of specific corticosteroid treatments in improving patient outcomes in this critical condition.\",9\n285,NEJM.ORG,\"NEJM.org is a website that serves as a comprehensive resource for medical professionals and researchers. It is recognized for publishing the full text of significant medical trials and studies, including the APROCCHSS trial article along with additional materials related to the trial. Furthermore, NEJM.org provides access to the full text of study protocols, ensuring that users have access to detailed methodologies and research findings in the medical field. This platform is essential for those seeking in-depth information and updates on medical research and trials.\",4\n1,ELI LILLY,\"Eli Lilly is a pharmaceutical company based in Indianapolis, known for producing drotrecogin alfa activated, also known as DrotAA or Xigris. This company has been actively involved in clinical studies to evaluate the drug's impact on patients with specific health conditions, notably funding the PROWESS-SHOCK trial for DrotAA. Through its commitment to research and development in the pharmaceutical field, Eli Lilly has established itself as a key player in advancing medical treatments and therapies.\",6\n370,APROCCHSS,The clinical trial named Activated Protein C and Corticosteroids for Human Septic Shock that evaluated the effect of hydrocortisone-plus-fludrocortisone therapy on septic shock patients,4\n372,XIGRIS,\"Xigris, the brand name for drotrecogin alfa (activated), was a drug used in the treatment of septic shock. It was the commercial form of drotrecogin alfa (activated) available on the market. However, Xigris was withdrawn from the market in October 2011. This withdrawal was due to concerns over its efficacy and safety, leading to its discontinuation. The decision to withdraw Xigris was consistent across all descriptions, highlighting its removal from the market in 2011 after being identified as a treatment option for septic shock.\",2\n376,COMITÉ DE PROTECTION DES PERSONNES D’ILE DE FRANCE XI,\"An independent ethics committee based in Saint-Germain-en-Laye, France, that approved the APROCCHSS trial protocol\",1\n379,SYNACTHEN,No Description,1\n378,SURVIVING SEPSIS CAMPAIGN GUIDELINES,\"Guidelines harmonized across centers for antiinfective treatments, hemodynamic and respiratory management, and blood glucose control in the APROCCHSS trial\",1\n374,HYDROCORTISONE-PLUS-FLUDROCORTISONE THERAPY,A treatment method tested in the APROCCHSS trial for patients with septic shock,1\n343,SEPSISPAM,\"A multicenter, open-label trial to determine the effectiveness of different mean arterial pressure targets during resuscitation of patients with septic shock\",4\n7,\"DROTRAA (XIGRIS, ELI LILLY)\",\"DrotAA (Xigris, Eli Lilly) is a drug administered as an intravenous infusion at a dose of 24 μg per kilogram of body weight per hour for 96 hours in a study to assess its efficacy in patients\",1\n3,EUROPEAN MEDICINES AGENCY,\"Regulatory body that granted marketing authorization for DrotAA for severe sepsis and multiple organ failure, subject to annual review\",1\n4,FOOD AND DRUG ADMINISTRATION,US regulatory agency that limited DrotAA's approval for use in patients with a high risk of death and requested additional trials,1\n6,PROWESS,No Description,1\n8,DUKE CLINICAL RESEARCH INSTITUTE,\"The Duke Clinical Research Institute performed the analysis for the study involving DrotAA (Xigris, Eli Lilly)\",1\n10,SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORES,No Description,1\n28,FRANCE,\"France is a country recognized for its contributions to medical research, notably in the field of critical care medicine. It was the location for a significant placebo-controlled, randomized, double-blind trial focusing on the use of corticosteroids for treating septic shock. Additionally, France hosted the SEPSISPAM trial, which was conducted across 29 centers throughout the country. These studies highlight France's role in advancing medical knowledge and treatment protocols in critical care and sepsis management.\",3\n383,GER-INF-05 TRIAL,A clinical trial that showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock,1\n384,HYPRESS TRIAL,A clinical trial where hydrocortisone alone failed to prevent septic shock in adults with severe sepsis,1\n344,ANGERS UNIVERSITY HOSPITAL,Institution whose ethics committee approved the SEPSISPAM trial,1\n371,FRENCH MINISTRY OF SOCIAL AFFAIRS AND HEALTH,The funding body for the APROCCHSS clinical trial through Programme Hospitalier de Recherche Clinique 2007,1\n373,PROGRAMME HOSPITALIER DE RECHERCHE CLINIQUE 2007,No Description,1\n342,FRENCH MINISTRY OF HEALTH,\"Organization that funded the SEPSISPAM trial, which investigates mean arterial pressure targets in septic shock resuscitation\",1\n281,NORTH WEST LONDON RESEARCH ETHICS COMMITTEE,Approved the study protocol related to the trial,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n76,SEPTIC SHOCK,DROTRECOGIN ALFA (ACTIVATED),\"Drotrecogin alfa (activated) was initially used in the treatment of septic shock before it was withdrawn from the market. This medication was specifically aimed at managing septic shock, a severe condition, but due to various reasons, it is no longer available for this purpose.\",84\n5,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,SEPTIC SHOCK,DrotAA was investigated for its efficacy in treating septic shock in the PROWESS-SHOCK trial,83\n79,SEPTIC SHOCK,HYDROCORTISONE PLUS FLUDROCORTISONE,The treatment regimen was used in clinical trials to assess its effectiveness in reducing mortality and the need for vasopressors in patients with septic shock,83\n81,SEPTIC SHOCK,INTENSIVE CARE UNITS (ICUS),\"Septic shock is a leading cause of death in ICUs, where the study's treatments were evaluated\",80\n15,SEPTIC SHOCK,GROUPE D'ETUDE ET DE RECHERCHE SUR LE MÉDICAMENT (GERMED),GERMED supported the study on corticosteroid treatment for septic shock,79\n75,SEPTIC SHOCK,HYDROCORTISONE-PLUS-FLUDROCORTISONE,\"The therapy was evaluated for its effectiveness in treating septic shock, showing a reduction in mortality\",79\n11,PROWESS-SHOCK,SEPTIC SHOCK,The PROWESS-SHOCK trial focused on patients with septic shock to assess the efficacy of DrotAA,79\n300,SEVERE SEPSIS,DROTRECOGIN ALFA (ACTIVATED),Drotrecogin alfa activated is used in the treatment of severe sepsis and has shown to reduce mortality rates,29\n414,DROTRECOGIN ALFA (ACTIVATED),APROCCHSS TRIAL,Drotrecogin alfa (activated) was one of the treatments tested in the APROCCHSS trial for septic shock,16\n571,APROCCHSS TRIAL,HYDROCORTISONE PLUS FLUDROCORTISONE,The APROCCHSS trial showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock,15\n526,NEJM.ORG,APROCCHSS TRIAL,The full text and additional materials of the APROCCHSS trial are published on NEJM.org,13\n415,DROTRECOGIN ALFA (ACTIVATED),HYDROCORTISONE PLUS FLUDROCORTISONE,The potential interaction between drotrecogin alfa (activated) and hydrocortisone plus fludrocortisone was not assessed due to the withdrawal of Xigris from the market,13\n10,ELI LILLY,DROTRECOGIN ALFA (ACTIVATED),Eli Lilly is the producer of drotrecogin alfa activated,13\n192,INTENSIVE CARE UNITS (ICUS),APROCCHSS TRIAL,Patients in ICUs were eligible for inclusion in the APROCCHSS trial,12\n412,DROTRECOGIN ALFA (ACTIVATED),APROCCHSS,The APROCCHSS trial was designed to evaluate drotrecogin alfa (activated) among other therapies for septic shock before its withdrawal,11\n566,XIGRIS,APROCCHSS TRIAL,The trial continued with two parallel groups after Xigris was withdrawn from the market,11\n568,APROCCHSS TRIAL,COMITÉ DE PROTECTION DES PERSONNES D’ILE DE FRANCE XI,The ethics committee approved the trial protocol for the APROCCHSS trial,10\n569,APROCCHSS TRIAL,SYNACTHEN,Synacthen was used in the APROCCHSS trial to measure cortisol levels as part of the trial's procedures,10\n570,APROCCHSS TRIAL,SURVIVING SEPSIS CAMPAIGN GUIDELINES,The APROCCHSS trial harmonized nonexperimental interventions across centers according to these guidelines,10\n567,HYDROCORTISONE-PLUS-FLUDROCORTISONE THERAPY,APROCCHSS TRIAL,The therapy was one of the treatments tested in the APROCCHSS trial for septic shock,10\n9,ELI LILLY,APACHE II SCORE,APACHE II score was used as a baseline characteristic in the Eli Lilly-sponsored study to examine the treatment effect on mortality,10\n276,SURVIVING SEPSIS CAMPAIGN,SEPSISPAM,The SEPSISPAM trial investigates the recommendations made by the Surviving Sepsis Campaign regarding mean arterial pressure targets,10\n413,DROTRECOGIN ALFA (ACTIVATED),XIGRIS,\"Drotrecogin alfa (activated), also known as Xigris, is a medication that was available under the brand name Xigris. It was withdrawn from the market in 2011. Xigris served as the commercial form of drotrecogin alfa (activated), indicating that both names refer to the same product. The withdrawal applies universally to the product, regardless of the name it was marketed under.\",9\n1,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,PROWESS-SHOCK,DrotAA was the subject of the PROWESS-SHOCK trial to test its efficacy in reducing mortality in septic shock patients,8\n515,CORTICUS TRIAL,HYDROCORTISONE PLUS FLUDROCORTISONE,\"The CORTICUS trial showed no significant survival benefit from hydrocortisone alone, contrasting with trials using hydrocortisone plus fludrocortisone\",8\n6,ELI LILLY,\"DROTRAA (XIGRIS, ELI LILLY)\",\"DrotAA (Xigris) is a product of Eli Lilly, indicating a direct product-company relationship\",7\n2,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,EUROPEAN MEDICINES AGENCY,\"The European Medicines Agency granted marketing authorization for DrotAA, subject to annual review\",7\n3,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,FOOD AND DRUG ADMINISTRATION,The FDA limited DrotAA's approval for use in patients with a high risk of death,7\n4,DROTRECOGIN ALFA (ACTIVATED) OR DROTAA,PROWESS,The PROWESS study was crucial in the initial approval of DrotAA for the treatment of severe sepsis,7\n7,ELI LILLY,DUKE CLINICAL RESEARCH INSTITUTE,\"The Duke Clinical Research Institute conducted the analysis for the study sponsored by Eli Lilly, indicating a collaboration between the institute and the company\",7\n8,ELI LILLY,SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORES,SOFA scores were used in the study sponsored by Eli Lilly to measure organ dysfunction and assess the efficacy of DrotAA,7\n164,FRANCE,SEPSISPAM,The SEPSISPAM trial was conducted across 29 centers in France,7\n572,HYDROCORTISONE PLUS FLUDROCORTISONE,GER-INF-05 TRIAL,The Ger-Inf-05 trial showed a survival benefit with hydrocortisone plus fludrocortisone in adults with septic shock,7\n573,HYDROCORTISONE PLUS FLUDROCORTISONE,HYPRESS TRIAL,\"The HYPRESS trial, focusing on hydrocortisone alone, failed to prevent septic shock, highlighting the potential effectiveness of adding fludrocortisone\",7\n525,NEJM.ORG,WRITING COMMITTEE,The manuscript prepared by the Writing Committee is available at NEJM.org,7\n563,HYDROCORTISONE-PLUS-FLUDROCORTISONE,APROCCHSS,The APROCCHSS trial evaluated the effectiveness of hydrocortisone-plus-fludrocortisone therapy in septic shock,6\n163,FRANCE,INTENSIVE CARE UNITS (ICUS),The ICUs involved in the septic shock study were located in France,6\n524,CLINICAL TRIALS UNIT AT THE UNITED KINGDOM INTENSIVE CARE NATIONAL AUDIT AND RESEARCH CENTRE (ICNARC),NEJM.ORG,Managed study details and supplementary appendix available at NEJM.org,6\n547,SEPSISPAM,ANGERS UNIVERSITY HOSPITAL,The ethics committee at Angers University Hospital approved the SEPSISPAM trial,5\n564,APROCCHSS,FRENCH MINISTRY OF SOCIAL AFFAIRS AND HEALTH,The APROCCHSS trial was funded by the French Ministry of Social Affairs and Health,5\n565,APROCCHSS,PROGRAMME HOSPITALIER DE RECHERCHE CLINIQUE 2007,The program funded the APROCCHSS clinical trial,5\n162,FRANCE,GROUPE D'ETUDE ET DE RECHERCHE SUR LE MÉDICAMENT (GERMED),The study was conducted in France and supported by GERMED,5\n546,FRENCH MINISTRY OF HEALTH,SEPSISPAM,The SEPSISPAM trial was funded by the French Ministry of Health,5\n522,NORTH WEST LONDON RESEARCH ETHICS COMMITTEE,NEJM.ORG,Study protocol approved by the committee is available at NEJM.org,5\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}